Emerging regulatory model of Ubiquitin-Specific Proteases 14 in cancer: from canonical oncogenesis to TME modulation, therapeutic resistance, and non-canonical activities Authors: RuoFeng Wang, Fang Yan, Fengrui Duan, Weikai Xia, Wenbo Wang, Zhenxiang Wang, Fulin Sun, Chunjuan Yu, Huhu Zhang, Lina Yang Published: 2026 ABSTRACT AbstractBackgroundUbiquitin-Specific Protease 14 (USP14) is a proteasome-associated deubiquitinase historically viewed as a pro-tumorigenic driver of the ubiquitin–proteasome system (UPS) by stabilizing oncoproteins. Recent evidence expands this view, positioning USP14 as a central regulator that integrates tumor cell–intrinsic malignancy, tumor microenvironment (TME) remodeling, and resistance to multiple therapies. Importantly, USP14 exerts functions beyond canonical deubiquitination, including non-catalytic and scaffolding activities, and is subject to complex allosteric regulation.Main bodyThis review synthesizes emerging regulatory crosstalks that broaden the functional landscape of USP14 in cancer. We first outline the dynamic allosteric regulatory network of USP14 and its activation modes, emphasizing post-translational modifications (PTMs)—notably phosphorylation and lactylation—that modulate USP14 activity and connectivity beyond traditional links to cell cycle control and metabolism. We then consolidate the signaling frameworks through which USP14 contributes to resistance across therapeutic modalities, including targeted therapies, chemotherapy, radiotherapy, and immunotherapy, highlighting both shared and treatment-specific mechanisms. In parallel, we discuss context-dependent tumor-suppressive roles of USP14 and detail its non-catalytic scaffolding functions that reshape signaling outputs independent of enzymatic activity. Collectively, these classical and non-classical mechanisms depict USP14 as a systems-level coordinator of oncogenic signaling, adaptive stress responses, and microenvironmental interactions.ConclusionsBy integrating catalytic and non-catalytic functions with PTM-driven allosteric regulation, we propose a unified regulatory model in which USP14 operates as a master node connecting malignancy, TME dynamics, and therapeutic resistance. This framework provides strategic guidance for developing next-generation allosteric inhibitors and combination strategies aimed at overcoming clinical drug resistance and exploiting context-specific vulnerabilities in USP14-regulated networks. Introduction Ubiquitination is a key post-translational modification in cells, where the specific type of ubiquitin linkage often determines the fate of a protein. Specifically, K48-linked ubiquitination is the most common form, typically marking proteins for degradation by the 26 S proteasome [1, 2]. Deubiquitinating enzymes (DUBs) counter this process. By cleaving the isopeptide or thioester bonds between ubiquitin chains and target proteins, DUBs remove the ubiquitin tags and protect proteins from degradation [3]. Ubiquitin-Specific Proteases (USPs) represent the largest DUB family, consisting of over 60 members with diverse structures and substrate specificities [4, 5]. Among these, USP14 has attracted particular attention for several reasons. First, unlike most USP family members that function as free enzymes in the cytoplasm or nucleus, USP14 is one of only three DUBs—along with UCHL5 and RPN11—that are physically associated with the 26 S proteasome, serving as a gatekeeper of proteasomal degradation. This unique positioning allows USP14 to intercept ubiquitinated substrates at the final checkpoint before their irreversible degradation, granting it a disproportionately broad influence over protein homeostasis. Second, accumulating evidence reveals that USP14 is not a simple oncogene; rather, it exerts context-dependent dual regulatory roles—both tumor-promoting and tumor-suppressive—depending on the cellular environment, available substrates, and interacting partners. This functional duality distinguishes USP14 from most other USP family members, which tend to exhibit more unidirectional roles in cancer. Third, USP14 plays a broad tumor-promoting role in approximately 61% of known cancers [6], and its regulatory scope extends beyond cell-autonomous effects to encompass tumor microenvironment remodeling and therapy resistance, making it a uniquely multifaceted therapeutic target. Mechanistically, before a ubiquitinated substrate fully enters the proteasome’s degradation chamber, USP14 removes the polyubiquitin chain. This action delays or prevents degradation, effectively “rescuing” the substrate. Early research largely focused on USP14 as a cell-autonomous factor, suggesting it drives malignant phenotypes by stabilizing oncogenic proteins [7]. However, cancer progression is not an isolated intracellular event [8]. It is highly relevant to the TME. In this complex environment consisting of stromal cells, immune cells, and the extracellular matrix, cancer cells interact with their surroundings, leading to the formation of “cold tumors.“ [9] USP14 helps build external conditions that lack active immune cells and favor cancer cell proliferation and migration, allowing the tumor to escape immune system control. Besides, evolutionary adaptations within cancer cells lead to therapy resistance, making the treatment of advanced tumors very challenging. Cancer cells develop different levels of primary or acquired resistance to targeted therapy, radiotherapy, chemotherapy, and immunotherapy [10]. This occurs through mechanisms such as target mutations, bypass activation, enhanced DNA repair, or increased cell death thresholds [11]. The deubiquitinating activity of USP14 is a critical factor in driving this resistance. Accumulating evidence suggests that USP14 acts as a key molecular hub linking cell-autonomous malignancy, TME remodeling, and adaptive therapy resistance. However, previous reviews have primarily focused on the structure, activity modifications, and therapeutic targets of USP14. With recent research advances, the understanding of USP14 complexity has expanded significantly. Yet, a systematic overview covering its dual regulatory roles in cancer, TME construction, and mechanisms of therapy resistance is still lacking [12, 13]. In this article, we summarize recent findings on USP14. We highlight that beyond its role as an upstream regulator of oncogenic proteins, USP14 possesses new functions, including shaping the TME, promoting therapy resistance, and exerting non-catalytic effects. We also propose that USP14 is not solely an oncogenic factor. Its function is often context-dependent, relying on specific regulatory environments and distinct upstream or downstream molecules. This review aims to integrate these emerging findings to provide a new, comprehensive regulatory framework for USP14 in cancer, offering fresh insights into strategies for targeting it therapeutically. Notably, however, USP14 is not a tumor-specific protein but plays essential physiological roles, particularly in the nervous system. USP14-deficient axJ mice exhibit severe tremors, hindlimb paralysis, and early lethality due to impaired synaptic ubiquitin homeostasis and neuromuscular junction development [14–17]. Neuronal-specific transgenic rescue restores viability, confirming that the primary physiological requirement for USP14 resides in the nervous system [17]. These observations underscore the need for caution in clinical translation, as systemic USP14 inhibition may carry risks of neurotoxicity and immune dysfunction. Molecular structure and regulation of USP14 activity Basic structure Human USP14 is a 494-amino acid protein homologous to yeast Ubp6. Its core architecture consists of an N-terminal ubiquitin-like (UBL) domain and a C-terminal catalytic (CAT) domain, connected by a highly flexible linker. The CAT domain, responsible for deubiquitination, adopts a hand-like structure composed of Fingers, Palm, and Thumb subdomains. In the resting state, the catalytic site is obstructed by specific blocking loops (BLs), maintaining the enzyme in an autoinhibited conformation(Fig. 1). The UBL domain functions as a molecular anchor, binding USP14 to the 26 S proteasome [18]. Interaction with the 19 S subunit not only accelerates proteasomal degradation rates but also induces a conformational change that relieves CAT domain autoinhibition, activating USP14. This dual action enhances both the efficiency and precision of protein degradation. Structure of USP14. Left: The overall structure of USP14, with its three domains colored in blue, green, and red. Right: A model showing the catalytic domain of USP14 bound to the potent small molecule inhibitor IU1-248. The BL1 and BL2 domains are respectively highlighted in red and orange [131] Dynamic modeling and activity regulation of autoinhibitory and UBL domains Early studies suggested that in free USP14, the active site of the CAT domain is occupied by its own BLs. This creates steric hindrance that inhibits enzyme activity. BL1, a key flexible loop located in the “Fingers” subdomain, physically prevents the C-terminus of ubiquitin chains or cofactors from accessing the substrate-binding channel housing the catalytic triad (Cys-His-Asp/Glu). Located adjacent to BL1, BL2 primarily functions to support and stabilize the autoinhibitory conformation of BL1. However, as research on USP14 progressed, scientists proposed a perspective that differs from early crystallographic models. Using NMR dynamic analysis, researchers discovered that BL1 and BL2 in free USP14 are highly dynamic in solution. Specifically, BL1 exhibits rapid dynamics (ps-ns), while the tip of BL2 displays slower chemical exchange dynamics (µs-ms). This behavior is controlled by a pre-existing dynamic allosteric network that spans the catalytic site, the ubiquitin-binding region, and the proteasome-binding site. Binding to the proteasome may trigger this network, transmitting allosteric signals to the catalytic site to relieve dynamic autoinhibition [19]. Cancer cells rely heavily on USP14 deubiquitinating activity to alleviate proteotoxic stress. Small molecule inhibitors such as IU1 work via allosteric regulation, locking USP14 into a state resembling its autoinhibited conformation. This novel dynamic allosteric model may offer new perspectives for studying the mechanism and development of small molecule inhibitors. Apart from the relief of autoinhibition induced by the UBL domain, the CAT domain is also regulated by phosphorylation at the post-translational level. Mediated by the AKT pathway, phosphorylation at Ser432 in the BL2 domain activates USP14(Fig. 4). This modification stabilizes the conformation, favoring the formation of a β-sheet structure in BL1. This structural change weakens the inhibition of the active site, thereby triggering USP14 activation. Furthermore, phosphorylation enhances critical hydrogen bonds and salt bridge interactions between USP14 and ubiquitin, which are essential for DUB activity [20]. Additionally, another study on hepatocellular carcinoma (HCC) revealed high levels of lactylation at Lys336 within the BL1 domain [21, 22]. This suggests that lactylation may influence the conformation of BL1, implying a functional “crosstalk” with the deubiquitinating activity of USP14 [23, 24]. Diverse mechanisms by which USP14 regulates the AKT pathway. (A) :The AKT pathway promotes phosphorylation of the BL2 domain in USP14. (B) :The roles of USP14 in driving tumorigenesis and drug resistance, as well as its critical tumor-suppressive function Recent studies have also revealed dynamic mechanisms within the N-terminal UBL domain of USP14. As a key anchor binding to the Rpn1 subunit of the 26 S proteasome, the UBL domain itself does not directly regulate catalytic activity. However, it exerts regulatory effects by mediating the interaction with the proteasome. Using combined NMR and SAXS analysis, researchers confirmed a transient inter-domain interaction between the UBL and USP domains. This interaction biases unbound USP14 toward a “bound-like” conformation. Consequently, it lowers the entropy cost of conformational rearrangement upon binding, significantly enhancing USP14 affinity for the proteasome and promoting its activation [25]. This “pre-organized” conformational feature is critical for cancer cell survival. Since tumor cells typically experience high rates of protein synthesis and proteasome load [26], the high affinity of USP14 ensures efficient binding to the 26 S proteasome, thereby maintaining the abundance of key oncoproteins. A schematic model integrating the structural basis, conformational activation, and functional outcomes of USP14-mediated deubiquitination is presented in Fig. 2. (Fig. 2) Mechanistic model of USP14 deubiquitination. (A) In the free state, blocking loops BL1 and BL2 obstruct the catalytic triad, maintaining USP14 in an autoinhibited conformation. A dynamic allosteric network and transient UBL–CAT interactions pre-organize USP14 for proteasome binding. (B) Upon association with the 19 S regulatory particle via the UBL domain, conformational change relieves autoinhibition. Phosphorylation at Ser432 (BL2) enhances DUB activity, while lactylation at Lys336 (BL1) may modulate catalytic regulation. (C) Functional outcomes are substrate- and context-dependent: deubiquitinated substrates are either rescued from degradation (canonical function) or translocated more efficiently into the 20 S core for facilitated degradation (non-canonical function) USP14 as a cell-autonomous cancer regulator Numerous studies indicate that USP14 modulates tumor growth and development via its deubiquitinase activity. We analyzed USP14 expression across various malignancies using RNA-seq data from The Cancer Genome Atlas (TCGA) database. Gene expression profiles (level 3 HTSeq-FPKM) were downloaded from the UCSC Xena platform (https://xenabrowser.net/) and converted to transcripts per million (TPM) values for cross-sample normalization. After excluding cancer types lacking matched normal tissue controls, a total of 32 cancer types with paired tumor and adjacent normal tissue samples were retained for analysis. Differential expression of USP14 between tumor and paired normal tissues was evaluated using the Wilcoxon rank-sum test, with statistical significance set at p < 0.05 (Fig. 3). Pan-cancer analysis revealed a statistically significant upregulation of USP14 expression in 13 cancer types: Breast Invasive Carcinoma (BRCA), Cholangiocarcinoma (CHOL), Colon Adenocarcinoma (COAD), Esophageal Carcinoma (ESCA), Head and Neck Squamous Cell Carcinoma (HNSC), Kidney Chromophobe (KICH), Kidney Renal Clear Cell Carcinoma (KIRC), Liver Hepatocellular Carcinoma (LIHC), Lung Adenocarcinoma (LUAD), Lung Squamous Cell Carcinoma (LUSC), Stomach Adenocarcinoma (STAD), Thyroid Carcinoma (THCA), and Uterine Corpus Endometrial Carcinoma (UCEC). Notably, recent studies have highlighted a tumor-suppressive role for USP14 in esophageal squamous cell carcinoma (ESCC) [27]. However, this is not reflected here due to the lack of specific tissue data in the TCGA database. Differential expression of USP14 in paired tumor and normal tissues. RNA-seq data (HTSeq-FPKM) from the TCGA database were downloaded via the UCSC Xena platform and normalized to log₂(TPM + 1). The Wilcoxon rank-sum test was used to compare USP14 expression between tumor tissues and matched adjacent normal tissues across 32 cancer types. Blue and red indicate normal and tumor tissues, respectively. Asterisks indicate statistical significance (*p < 0.05, **p < 0.01, ***p < 0.001) In most existing literature, USP14 is typically viewed as a promoter of cancer progression, a view supported by our TCGA analysis. Mechanistically, USP14 primarily uses its deubiquitinating activity to remove ubiquitin chains from proteins that directly or indirectly regulate tumorigenesis. This stabilizes these proteins and protects them from proteasomal degradation. The resulting accumulation of these specific proteins then modulates cancer initiation and progression through various pathways. However, evolving research has challenged the notion that USP14 is solely an oncogenic factor. Recent findings indicate that USP14 exerts opposing effects—both oncogenic and tumor-suppressive—on the PI3K/AKT pathway depending on the cellular context [27]. This suggests its function is dictated by the available substrates and interacting molecules within a specific environment. As a cell-autonomous regulator, USP14 mainly exerts its effects in four areas: regulating cell cycle and proliferation, inhibiting apoptosis and senescence, remodeling tumor metabolism, and promoting invasion and metastasis. (Table 1) Table 1USP14 in different cancersCancer typeTargetUSP14 actionFunctional consequenceBreast cancerCyclin B1Deubiquitinates and stabilizes Cyclin B1Promotes cell-cycle progression and proliferation.CDK1Removes K48-linked ubiquitin chains and stabilizes CDK1Cooperates with Cyclin B1 to prevent G2/M arrest and drive proliferation.PBX3Recruited by ATRAP for deubiquitination and stabilization of PBX3Activates AKT/mTOR-associated glycolytic signaling and promotes malignant progression.ARDeubiquitinates and stabilizes androgen receptorSustains pro-survival signaling and contributes to enzalutamide resistance.Triple-negative breast cancerSurvivinDeubiquitinates and maintains high Survivin levelsSuppresses apoptosis and supports tumor cell survival.BRCA1-deficient triple-negative breast cancerc-MycStabilizes nuclear c-MycSuppresses error-prone NHEJ and supports adaptation to PARP/PARG-related stress.Colorectal cancerJNKStabilizes JNK and prolongs its half-lifeAmplifies MAPK/JNK-AP1 signaling and promotes tumorigenesis and proliferation.S100A11Deubiquitinates and stabilizes S100A11Inhibits cellular senescence and promotes tumor progression.ATG7Deubiquitinates and stabilizes ATG7Enhances autophagy, supports growth, and suppresses apoptosis.IDO1Removes K48-linked ubiquitin chains and stabilizes IDO1Promotes tryptophan catabolism, suppresses IFN-γ and granzyme production, increases Tregs, and drives immune evasion.BAG4Deubiquitinates and stabilizes BAG4Inhibits Parkin-related mitophagy and contributes to oxaliplatin resistance.MYCMYC decreases after USP14 knockout; this is presented as part of a non-catalytic mechanismSupports the idea that USP14 also promotes CRC through non-catalytic functions. This one is less secure as a classic direct substrate.Gastric cancerSDC2Deubiquitinates and stabilizes SDC2Activates PDK1/AKT and FGF2-AKT signaling, promoting proliferation, growth, and invasion.VimentinDeubiquitinates and stabilizes VimentinPromotes EMT, invasion, and metastasis.KPNA2Removes K48-linked ubiquitin chains and stabilizes KPNA2Facilitates c-MYC nuclear translocation and enhances migration and invasion.SIRT1Interacts with and stabilizes SIRT1 in TAMsPromotes PGC1-α/FAO signaling, favors M2 macrophage polarization, and supports a tumor-promoting microenvironment.IMP2Removes K48-linked ubiquitin chains and stabilizes IMP2 in TAMsEnhances CXCL2 expression and secretion, recruits MDSCs, and promotes immune suppression and PD-1 therapy resistance.Hepatocellular carcinomaHK2Deubiquitinates and stabilizes HK2Promotes glycolysis, AKT/P62-associated signaling, and tumor growth.HIF1-αDeubiquitinates and stabilizes HIF1-αSupports proliferation, invasion, migration, and vasculogenic mimicry under hypoxia.MEF2DStabilizes MEF2D after FAK-dependent USP14 phosphorylationPromotes adhesion, chemotaxis, colonization, and intrahepatic metastasis.GLUT1Removes K48-linked ubiquitin chains and stabilizes GLUT1Enhances glucose competition against CD8 + T cells and drives immune escape.CIB1Deubiquitinates and stabilizes CIB1Activates the PAK1-ERK1/2 axis and contributes to lenvatinib resistance.GPX4Deubiquitinates and stabilizes GPX4Suppresses ferroptosis and promotes radioresistance.Non-small cell lung cancerEGFRDeubiquitinates EGFR after endocytosis, prevents degradation, and promotes membrane recyclingSupports tumor growth and also contributes to cisplatin resistance.Acf7Removes K63-linked ubiquitin chains and stabilizes Acf7Enhances migration and metastatic potential.CERS1Identified as an interacting tumor-suppressive partner of USP14Associated with reduced PI3K/AKT/mTOR signaling and suppression of migration, invasion, proliferation, and blood-brain barrier crossing. This is more consistent with an interaction partner than a classical USP14 substrate.Lung cancerBeclin1Removes K63-linked ubiquitin chains from Beclin1 and inhibits its functionBlocks autophagy and ferritinophagy, suppresses ferroptosis, and promotes survival.Pancreatic ductal adenocarcinomaTAZRemoves ubiquitin modifications from TAZ and stabilizes itPromotes liver metastasis and forms a positive feedback loop with USP14.PD-L1Removes K63-linked ubiquitin chains from PD-L1 and promotes its surface accumulationDrives T-cell exhaustion, immune escape, and immunotherapy resistance.Esophageal squamous cell carcinomaPIK3IP1Deubiquitinates and stabilizes PIK3IP1 in the presence of PDE5A-500aaInhibits PI3K/AKT signaling and suppresses ESCC progression.Head and neck squamous cell carcinomaIκBαDeubiquitinates IκBα and facilitates its proteasomal degradationSustains NF-κB signaling, inhibits apoptosis, and supports survival. This is a non-canonical degradation-promoting case.Multiple myelomaBcl-xlReported as being regulated by USP14 at the expression levelSuppresses apoptosis and supports survival. The review does not present this as a firmly defined classic deubiquitinated substrate.GlioblastomaALKBH5Removes K48-linked ubiquitin chains and stabilizes ALKBH5Enhances DNA repair, homologous recombination, stemness, and radioresistance.Prostate cancerRNF168Antagonizes RNF168 ubiquitination and ultimately destabilizes RNF168 through a non-canonical mechanismRestricts NHEJ and weakens radioresistance. This is another non-canonical case. USP14 in different cancers Regulating cell cycle and proliferation The cell cycle is a central governor of cell proliferation, and its deregulation is a hallmark of cancer. Early research in breast cancer showed that USP14 stabilizes Cyclin B1 via deubiquitination, thereby regulating cell cycle progression [28]. More recent insights reveal that USP14 stabilizes CDK1 by removing K48-linked ubiquitin chains, protecting it from proteasomal degradation. The accumulated CDK1 collaborates with Cyclin B1 to prevent G2/M checkpoint arrest, leading to uncontrolled proliferation [29, 30]. Similarly, USP14 is upregulated in colorectal cancer (CRC), where it stabilizes JNK protein and extends its intracellular half-life. This amplification of MAPK/JNK signaling allows activated JNK to translocate into the nucleus and trigger the key transcription factor AP-1. This cascade alters the cell cycle and drives CRC tumorigenesis [31]. Additionally, earlier reports indicated that USP14 knockdown arrests the cell cycle in HCC and non-small cell lung cancer (NSCLC) [32]. Collectively, these findings suggest USP14 is a potential therapeutic target for modulating the cell cycle in cancer. Beyond regulating core cell cycle components like Cyclins and CDKs, USP14 modulates proliferation through diverse pathways. In gastric cancer (GC), USP14 interacts with and deubiquitinates the membrane protein SDC2, protecting it from degradation. Stabilized SDC2 activates the AKT pathway by interacting with the kinase PDK1 and further amplifies AKT signaling via the FGF2-AKT axis [33](Fig. 4). This mechanism promotes GC cell proliferation, growth, and invasion. As USP14 is the critical upstream stabilizer of SDC2, inhibiting it with small molecules like IU1 has been shown to suppress cancer progression effectively [34]. In NSCLC, the abundance of membrane-bound EGFR is dynamically controlled by endocytosis and ubiquitination. Following endocytosis, mutant EGFR is often targeted by USP14 and its partner UCHL5, which remove ubiquitin chains. This prevents degradation and promotes the recycling of EGFR back to the cell membrane. Through this cell-autonomous mechanism, USP14 drives NSCLC development and is considered a promising therapeutic target [35]. Similarly, in HCC cells, USP14 stabilizes Hexokinase 2 (HK2) via deubiquitination [36]. Protected from proteasomal degradation, HK2 promotes the phosphorylation and activation of downstream AKT, thereby positively regulating cell growth and proliferation [37] (Fig. 4). Notably, USP14 exhibits a tumor-suppressive role in ESCC by negatively regulating cell proliferation. In this context, USP14 acts as a mediator that stabilizes tumor-suppressor proteins to curb cancer progression. Research shows that the circular RNA circPDE5A encodes a novel protein, PDE5A-500aa. This protein enhances the interaction between USP14 and PIK3IP1, promoting its deubiquitination. Since PIK3IP1 is an inhibitor of the oncogenic PI3K/AKT pathway, its increased stability suppresses ESCC development [27] (Fig. 4). This unique pathway highlights the dual effects of USP14 in cancer regulation, demonstrating that its specific function is dictated by local regulatory factors and underscoring the complexity of its mechanisms. Inhibiting apoptosis and senescence Evading cell death and resisting senescence are essential for cancer cells to acquire limitless proliferative potential and maintain a long-term survival advantage [38]. Early research indicated that USP14 downregulates apoptosis in multiple myeloma cells by modulating the expression of Bcl-xl [39]. Additionally, USP14 negatively regulates ER stress-mediated autophagy in NSCLC and HCC cells. This occurs through the inhibition of JNK1 and the promotion of Notch1 and Wnt/β-catenin signaling, respectively [40]. In CRC, USP14 deubiquitinates S100A11, preventing its proteasomal degradation and increasing its intracellular abundance. S100A11 promotes cancer progression by downregulating senescence-associated proteins to inhibit cellular senescence. These findings suggest that targeting the USP14-S100A11 axis may offer a promising therapeutic strategy for CRC [41]. Additionally, recent research in triple-negative breast cancer identifies Survivin as an apoptosis inhibitor that maintains high levels due to USP14-mediated deubiquitination. Based on this, researchers propose that the cholesterol-lowering drug Lovastatin can effectively target USP14 to induce apoptosis [42]. In head and neck squamous cell carcinoma (HNSCC), USP14 also promotes the degradation of IκBα to sustain NF-κB signaling activation, thereby protecting cancer cells from apoptosis [43]. Remodeling tumor metabolism Metabolic reprogramming is key for cancer cells to adapt to microenvironmental stress. By regulating intracellular metabolic states, USP14 enhances adaptation to adverse conditions and meets the metabolic demands for proliferation, thereby driving tumor initiation and progression [44]. While early research in this area was limited, recent studies have focused on three main aspects: regulating energy metabolism, responding to hypoxic stress, and modulating autophagy. In breast cancer, Angiotensin II Type 1 Receptor-Associated Protein (ATRAP) is highly expressed [45]. It acts as an adaptor, recruiting USP14 to deubiquitinate and stabilize PBX3. The upregulated PBX3 then activates the AKT/mTOR pathway via phosphorylation, promoting glycolysis to provide energy for tumor development [46, 47] (Fig. 4). Similar glycolytic regulation occurs in HCC cells. USP14 deubiquitinates Hexokinase 2 (HK2), maintaining its stability. High levels of HK2 directly increase the glycolytic rate. Additionally, HK2 activates downstream Sequestosome 1 (SQSTM1) via phosphorylation, positively regulating both glycolysis and autophagy [37]. USP14 also mediates the response to hypoxic stress in HCC cells. In the hypoxic microenvironment, USP14 deubiquitinates and stabilizes HIF1-α. The accumulated HIF1-α binds to Hypoxia Response Elements (HREs) of target genes to activate transcription. USP14 knockdown arrests the cell cycle, demonstrating that USP14 relies on HIF1-α to promote proliferation, invasion, migration, and vasculogenic mimicry under hypoxia. This suggests USP14 has potential as a biomarker for early diagnosis and treatment [48]. Research on USP14-mediated autophagy primarily focuses on CRC and lung cancer (LC) cells. In CRC, the protein EIF4A3, encoded by circEIF4A3, binds to USP14 mRNA to prevent its degradation, thereby increasing USP14 abundance. USP14 then deubiquitinates ATG7, protecting it from the proteasome. As a key autophagy protein, upregulated ATG7 promotes autophagy, supporting CRC growth and proliferation while inhibiting apoptosis [49]. Conversely, in LC cells, USP14 targets the key autophagy protein Beclin1. By removing K63-linked ubiquitin chains, USP14 inhibits Beclin1 function, blocking the autophagy process. Ferroptosis in LC relies on ferritinophagy and ROS accumulation. Since autophagy is inhibited, ferritin cannot mediate the subsequent apoptotic process. Consequently, cancer cells fail to initiate ferroptosis, leading to resistance and promoting tumor survival and proliferation [50]. Influencing cell invasion and metastasis Distant metastasis is the primary cause of cancer-related mortality. To metastasize, cancer cells must be highly invasive, motile, and adaptable to harsh microenvironments. They achieve this spread by undergoing epithelial-mesenchymal transition (EMT), remodeling their cytoskeleton, and enhancing their adhesion and colonization capabilities [51]. Previous studies indicated that in GC, USP14 promotes invasion and metastasis by stabilizing Vimentin, a key marker of EMT [52]. Subsequent research identified the specific regulatory mechanism: the m6A reader protein YTHDF1 binds to USP14 mRNA, enhancing its translation efficiency and increasing intracellular USP14 levels. USP14 then exerts its deubiquitinating activity to promote Vimentin-mediated metastasis in GC cells [53]. Additionally, a novel mechanism was discovered in GC. USP14 specifically removes K48-linked ubiquitin chains from KPNA2, preventing its proteasomal degradation and stabilizing its expression. Mediated by USP14, stabilized KPNA2 interacts with the key oncoprotein c-MYC. This promotes the nuclear translocation of c-MYC, activating downstream genes that drive GC cell migration and invasion [54]. In HCC, early studies suggested that USP14 promotes metastasis by deubiquitinating and activating the PI3K/AKT signaling pathway(Fig. 4). Recent findings reveal that USP14 also functions as a crucial intermediate regulator in disseminated tumor cells (DCCs) of HCC. Upon sensing pro-metastatic signals, integrins in DCCs activate the FAK signaling pathway, which phosphorylates USP14 at Ser432. Activated USP14 stabilizes MEF2D via deubiquitination. This regulates downstream integrin expression, enabling cancer cells to undergo adhesion, chemotaxis, and colonization, thereby promoting intrahepatic metastasis [55]. In the liver metastasis of pancreatic ductal adenocarcinoma (PDAC), USP14 specifically removes ubiquitin modifications from TAZ, a Hippo pathway effector, protecting it from degradation [56, 57]. Conversely, TAZ regulates the transcriptional expression of USP14, creating a positive feedback loop that enhances the metastatic potential of cancer cells [58]. In the context of NSCLC metastasis, USP14 exhibits a dual regulatory role, acting as both a promoter and an inhibitor. On one hand, USP14 is highly expressed in lung cancer and stabilizes Acf7 by removing K63-linked ubiquitin chains, thereby increasing its intracellular abundance. The upregulation of Acf7 significantly promotes the migration capability of NSCLC cells [59, 60]. On the other hand, regarding brain metastasis common in NSCLC, USP14 has been identified as an interacting partner of the tumor suppressor CERS1, contributing to metastasis suppression. Research indicates that in NSCLC, CERS1 interacts with USP14 to negatively regulate downstream signaling. This interaction significantly reduces the phosphorylation and activation of the PI3K/AKT/mTOR pathway, ultimately inhibiting cell migration, proliferation, invasion, and the ability to cross the blood-brain barrier [61] (Figs. 4 and 5). Regulatory landscape and mechanisms of USP14 across various malignancies. Brain Malignancies: USP14 mediates radioresistance in glioblastoma, functioning as a metastasis suppressor in lung-to-brain metastasis models. ESCC: USP14 acts as a tumor suppressor through the PDE5A-500aa/PIK3IP1 axis. Breast Cancer: USP14 stabilizes AR causing drug resistance, drives glycolysis, and mediates PARP inhibitor resistance by modulating the NHEJ/HR repair pathway switch. GC: USP14 facilitates M2 macrophage polarization and MDSC recruitment to shape an immunosuppressive microenvironment. HCC: USP14 mediates T cell exhaustion induced by glucose competition, Lenvatinib resistance, and hypoxia adaptation. CRC: USP14 contributes to immune escape and 5-FU resistance; its loss triggers a cellular senescence phenotype. NSCLC: USP14 mediates cisplatin resistance, promotes invasion and metastasis, and regulates cell cycle progression USP14 shapes the tumor microenvironment USP14 impairs T cell function In HCC, intracellular USP14 removes K48-linked ubiquitin chains from GLUT1, preventing its proteasomal degradation. As membrane GLUT1 levels rise, HCC cells outcompete CD8+ T cells for glucose, creating a glucose-deprived microenvironment. Starved of energy, CD8+ T cells lose their immune efficacy, leading to immune escape (Fig. 6). Since resistance to CD8+ T cell-based immunotherapy is common in HCC, this finding provides preliminary evidence for using USP14 inhibitors to overcome drug resistance [62, 63]. Regulatory roles of USP14 in shaping the tumor microenvironment. (A) USP14 induces immune cell exhaustion in HCC and CRC via distinct pathways. (B) USP14 promotes M2 macrophage polarization in GC. (C) USP14 facilitates the recruitment of MDSCs into the tumor microenvironment In CRC, USP14 not only shapes the microenvironment against cytotoxic T cells but also directly regulates interferon secretion. USP14 removes K48-linked ubiquitin chains from IDO1, preventing its proteasomal degradation and maintaining high intracellular levels. As IDO1 is a key enzyme for tryptophan degradation, its upregulation leads to tryptophan depletion and kynurenine accumulation. This metabolic shift suppresses interferon-gamma (IFN-γ) secretion while simultaneously reducing granzyme levels in CD8+ T cells and increasing the percentage of suppressive CD25+FOXP3+ regulatory T cells (Tregs) (Fig. 6). Together, these changes establish an immune-evasive environment that drives CRC progression [64]. USP14 polarizes M2 macrophages In GC, USP14 exerts its regulatory effects primarily within tumor-associated macrophages (TAMs) rather than cancer cells, altering the TME to promote tumorigenesis. In macrophages, USP14 interacts with SIRT1, extending its half-life and increasing its stability. As a key lipid metabolism regulator, SIRT1 activates downstream PGC1-α, promoting fatty acid oxidation (FAO). Metabolic status often dictates macrophage function; FAO-dominant macrophages typically adopt the tumor-promoting M2 phenotype [65]. These M2 macrophages create an immunosuppressive microenvironment, releasing cytokines that facilitate GC cell migration and invasion while inducing EMT [66] (Fig. 6). Thus, inhibiting USP14 represents a potential therapeutic strategy for GC [67]. Recruiting myeloid-derived suppressor cells USP14 also functions within TAMs during GC development. Acting as a deubiquitinase, USP14 interacts with the m6A reader protein IMP2, removing K48-linked ubiquitin modifications to significantly stabilize IMP2 and extend its half-life [68]. IMP2 then interacts with CXCL2 mRNA to enhance its stability, upregulating the expression and secretion of CXCL2 protein [69]. As a chemokine, secreted CXCL2 potently recruits myeloid-derived suppressor cells (MDSCs) into the gastric cancer TME, triggering a strong immunosuppressive response [70] (Fig. 6). USP14 mediates multiple forms of therapy resistance Therapy resistance is a core challenge in clinical oncology and a primary cause of relapse and poor prognosis. Cancer cells often adapt to therapies by activating bypass signals, enhancing drug metabolism, or remodeling the microenvironment. With increasing research on resistance, we established a comprehensive model of USP14-mediated regulation, covering resistance to targeted therapy, radiotherapy, chemotherapy, and immunotherapy. Targeted therapy resistance Targeted therapy marks the era of precision oncology, yet acquired resistance driven by target mutations, bypass activation, or protein accumulation limits long-term efficacy [71]. In breast cancer, USP14 mediates resistance to the androgen receptor (AR) antagonist enzalutamide. USP14 deubiquitinates AR, preventing its proteasomal degradation. High intracellular AR levels sustain pro-survival signaling (PI3K/AKT and Wnt/β-catenin), reducing sensitivity to enzalutamide(Fig. 4). Blocking USP14 with IU1 or gene silencing restores AR degradation(Fig. 7). Furthermore, USP14 inhibition acts synergistically with enzalutamide to induce cell cycle arrest and caspase-dependent apoptosis, effectively reversing resistance [72]. Landscape of USP14-mediated regulatory mechanisms in therapeutic resistance. (A) USP14 promotes resistance to targeted therapies by targeting AR and CIB1. (B) USP14 confers radioresistance by enhancing DNA repair and inhibiting ferroptosis. (C) USP14 mediates resistance to immunotherapy by modulating PD-1/PD-L1 blockade targets. (D) USP14 drives chemoresistance by activating AKT and NF-κB pathways while suppressing mitophagy In BRCA1-deficient triple-negative breast cancer, resistance to PARP inhibitors is a significant hurdle. USP14 acts as a protective factor in BRCA1-mutant cells by stabilizing nuclear c-Myc, which suppresses Non-Homologous End Joining (NHEJ) [73–75]. When PARG inhibitors induce massive DNA double-strand breaks, USP14 prevents the hyperactivation of error-prone NHEJ [76]. This protects cancer cells from catastrophic genomic instability and death caused by erroneous repair [77] (Fig. 7). In HCC resistant to lenvatinib, USP14 is significantly upregulated. It stabilizes Calcium and Integrin Binding protein 1 (CIB1), preventing degradation. Accumulated CIB1 activates the downstream PAK1-ERK1/2 axis. Sustained ERK activation drives resistance [78] (Fig. 7). Consequently, targeting any node in the USP14-CIB1-ERK1/2 pathway may reverse this resistance [79, 80]. Radiotherapy resistance Acquired radioresistance remains a major cause of treatment failure. USP14 confers survival advantages by stabilizing key DNA damage response (DDR) molecules or blocking radiation-induced cell death, such as ferroptosis [81]. In NSCLC, USP14 regulates the balance of DNA repair pathways. Radiation causes double-strand breaks (DSBs), recruiting upregulated USP14 to damage sites. USP14 suppresses error-prone NHEJ while promoting high-fidelity Homologous Recombination (HR) [82]. Disrupting this balance via gene knockdown or drug inhibition sensitizes cells to radiation [83]. Conversely, in autophagy-deficient prostate cancer, USP14 antagonizes RNF168 ubiquitination and destabilizes the protein through non-canonical activity. This restricts NHEJ expression, thereby weakening radioresistance [84] (Fig. 7). In glioblastoma (GBM), ionizing radiation activates the kinase MST4. Phosphorylated ALKBH5 recruits USP14, which removes K48-linked ubiquitin chains from ALKBH5. This upregulation of ALKBH5 activates downstream DNA repair pathways, promoting HR and tumor stem cell self-renewal [85]. Radiation also kills cells via ROS-induced ferroptosis [86]. In HCC, USP14 stabilizes GPX4 via deubiquitination. GPX4 reduces toxic lipid peroxides to non-toxic alcohols, inhibiting ferroptosis [87, 88](Fig. 7). Inhibiting USP14 enhances ferroptosis and amplifies the anti-tumor immune response following radiotherapy [89]. Chemotherapy resistance Chemotherapy failure often results from complex adaptive survival mechanisms. USP14 plays a core role here by stabilizing substrates that regulate inflammation, metabolism, and proliferation, thereby raising the survival threshold. 5-Fluorouracil (5-FU) is a first-line CRC drug. High expression of USP14 and UCHL5 activates the NF-κB pathway, promoting p65 phosphorylation and nuclear translocation. This upregulates anti-apoptotic genes, inducing resistance. The small molecule inhibitor b-AP15 blocks NF-κB activation and impairs proteasome function [90]. This triggers proteotoxic stress and ROS accumulation, activating caspase-dependent apoptosis to kill resistant cells [91, 92]. In microsatellite-unstable CRC, USP14 mediates resistance to oxaliplatin, which relies on mitochondrial apoptosis [93]. USP14 stabilizes BAG4 via deubiquitination. BAG4 negatively regulates Parkin (PRKN), preventing the initiation of mitophagy and conferring resistance [94](Fig. 7). Blocking the USP14-BAG4 interaction with interfering peptides offers a potential strategy [95]. In NSCLC, USP14 stabilizes EGFR, activating the downstream PI3K/AKT pathway to promote cisplatin (DDP) resistance(Fig. 4). To address this, researchers developed aptamer-guided nano-zinc carriers to deliver siUSP14, effectively silencing USP14 and reversing resistance [96] (Fig. 7). Additionally, USP14 mediates gefitinib resistance by maintaining stemness and inhibiting apoptosis. MicroRNA-124a directly targets USP14 expression, reducing stemness and increasing sensitivity to gefitinib [97]. Immunotherapy resistance Immunotherapy, particularly PD-1/PD-L1 blockade, is promising but limited by immunosuppressive TMEs [98, 99]. USP14 regulation of immunotherapy resistance has been reported in GC and PDAC. In GC, USP14 may contribute to resistance to PD-1 blockade through TAM-mediated immunosuppressive remodeling of the TME, as detailed in Section “Recruiting myeloid-derived suppressor cells”. Briefly, activation of the USP14–IMP2–CXCL2 axis promotes MDSC accumulation and suppresses effective CD8 + T-cell responses, thereby favoring immune escape [70]. In PDAC, USP14 directly regulates PD-L1 on cancer cells to induce immune tolerance. Autophagy in TME fibroblasts leads to IL-6 secretion, which induces USP14 expression via STAT3 [100, 101]. USP14 specifically removes K63-linked ubiquitin chains from PD-L1. This causes PD-L1 accumulation on the cell surface, driving T cell exhaustion and immune escape [102](Fig. 7). Non-canonical functions and future therapeutic perspectives Most functions of USP14 rely on its deubiquitinating activity, through which it regulates cellular processes by acting on specific substrate proteins. However, growing research indicates that the physiological role of USP14 extends beyond this. Its non-catalytic activity and ability to promote protein degradation have recently been identified. These findings offer new potential targets for future drug design. Non-catalytic activity of USP14 A study in CRC cells revealed significant differences between the consequences of genetic knockout and pharmacological inhibition of USP14. USP14 knockout induced a senescence-like phenotype, characterized by the upregulation of the cell cycle inhibitor p21 and cell cycle arrest. Simultaneously, both mRNA and protein levels of the oncogene MYC were significantly downregulated. In contrast, inhibition using the specific inhibitor IU1 failed to reproduce these growth-suppressive and senescence phenotypes. This groundbreaking finding suggests that USP14 promotes CRC through mechanisms beyond its enzymatic activity, involving non-catalytic functions [103]. This offers a new perspective for targeting USP14 in cancer. It explains the potential failure of enzyme inhibitors like IU1 and clarifies the pleiotropy of USP14. Bioinformatics analysis of BioGRID protein interaction data identified USP14 interactors linked to actin cytoskeleton remodeling, DNA damage repair, mRNA splicing, ribosome, and stress granule formation [104]. Among these, the role of USP14 in DNA repair has been experimentally validated across multiple cancer types [82–85], and USP14 knockout cells exhibit altered morphology and actin distribution consistent with cytoskeletal involvement [103, 104]. However, the functional relevance of USP14 in ribosome/translation regulation and mRNA splicing remains to be experimentally confirmed. These findings collectively imply that USP14 may act as a scaffold for organizing diverse protein complexes, rather than functioning solely as a deubiquitinase. Promoting protein degradation As mentioned in the structure section, USP14 binds to the proteasome via its UBL domain [105]. This allows it to not only rescue proteins by trimming ubiquitin tags but also directly promote proteasomal degradation. USP14 exerts this non-canonical degradation-promoting activity in the negative regulation of RNF168 stability. Research shows that while USP14 deubiquitinates RNF168, the ultimate result is a massive reduction in RNF168 abundance [84, 106]. Similarly, in HNSCC, USP14 interacts with IκBα, a key inhibitor of the NF-κB pathway. It removes ubiquitin chains from IκBα, which then facilitates its delivery to the proteasome for degradation [43]. A similar effect occurs with Defective Ribosomal Products, where USP14 deubiquitination precedes proteasomal degradation [107]. In these cases, deubiquitination likely reduces steric hindrance, making it easier for proteins to enter the proteasome. Thus, for certain proteasome-sensitive substrates, USP14 accelerates their clearance rather than protecting them. Future therapeutic perspectives Current inhibitors targeting USP14 are relatively mature and fall into two main categories: covalent inhibitors (e.g., b-AP15 and VLX1570) that bind to the cysteine residue in the catalytic center, and allosteric inhibitors (e.g., IU1 and its derivatives) that physically block enzyme activity by binding to an allosteric pocket [108]. However, the clinical development of VLX1570 has provided a sobering lesson regarding the translational bottlenecks facing USP14 inhibitors. In a phase 1 clinical trial (NCT02372240), fourteen patients with relapsed and/or refractory multiple myeloma were treated with escalating doses of VLX1570 (0.05–1.2 mg/kg) administered as intravenous infusions in combination with low-dose dexamethasone. While modest anti-myeloma activity was observed at doses at or above 0.6 mg/kg, two patients treated at the 1.2 mg/kg dose level developed severe, abrupt, and progressive pulmonary toxicity characterized by diffuse bilateral pulmonary infiltrates and respiratory insufficiency, culminating in death [109]. The steep dose–toxicity relationship and the narrow therapeutic window led to study termination. This outcome underscores several critical challenges for USP14-targeted drug development. First, VLX1570, as a covalent inhibitor, simultaneously targets both USP14 and UCHL5—two proteasome-associated DUBs that share a similar catalytic architecture—raising the concern that dual inhibition may amplify off-target toxicity in normal tissues [110]. Second, the poor aqueous solubility of VLX1570 necessitated a formulation containing polyethylene glycol, polyoxyethylated castor oil, and polysorbate 80, which may have contributed to the observed pulmonary adverse events [109]. Third, the absence of reliable pharmacodynamic biomarkers precluded precise monitoring of on-target DUB inhibition in vivo, making dose optimization difficult. These findings collectively highlight the urgent need for next-generation USP14 inhibitors with improved target selectivity, favorable pharmacokinetic profiles, and wider therapeutic indices. In parallel, the development of companion biomarkers to monitor USP14 engagement in tumors versus normal tissues will be essential for guiding future clinical trials. Broad-spectrum metal complex inhibitors and natural product inhibitors have also been identified. Beyond small molecular inhibitors, novel agents like 6-Gingerol suppress USP14 expression and inhibit NSCLC progression [50]. The Chikungunya virus inhibitor AKOS and the cholesterol-lowering drug Lovastatin show therapeutic efficacy against CRC as small molecule inhibitors of USP14 [42, 111] (Table 2). An siRNA nanodelivery system has also been developed to achieve complete in vivo inhibition of USP14 activity, demonstrating potent reversal of drug resistance [96]. This proof-of-concept study highlights the potential of nanomaterial-based platforms to overcome the pharmacokinetic limitations and off-target effects associated with systemic administration of free inhibitors. In particular, stimuli-responsive nanoparticles—such as pH-sensitive, ROS-responsive, or enzyme-activated carriers—could enable tumor-selective release of USP14 inhibitors or siRNAs within the acidic and oxidative tumor microenvironment [112]. Lipid nanoparticles (LNPs) and polymeric nanocarriers, which have demonstrated clinical success in nucleic acid delivery, may serve as viable platforms for delivering USP14-targeting agents [113]. Furthermore, antibody-drug conjugates (ADCs) or aptamer-drug conjugates could enhance the precision of delivery to defined cancer subtypes [114]. Given that USP14 operates at the interface of cell-autonomous signaling, TME remodeling, and therapy resistance, combining nanomaterial-delivered USP14 inhibitors with immune checkpoint blockade or conventional chemotherapy may yield synergistic effects [115]. Most current research relies on IU1 to reverse USP14 function; exploring diverse inhibitor types may advance clinical drug development with new structural insights. Table 2Different kinds of USP14 inhibitorCategoryCompoundIC50SelectivityStructureRefsAllostericIU14.7 µMHigh [129]IU1-470.6 µMHigh [130]IU1-2480.83 µMHigh [131]AKOS0.98 µMMedium [111]Covalentb-AP15~ 1 µMMedium (Specific to USP14&UCHL5) [108, 132, 133]VLX15700.58 µMLow [134]WP11302.5-5.0 µMLow (Broad-spectrum) [135]Metal ComplexAuranofin-Medium (Specific to USP14&UCHL5) [136]NiPT-Medium (Specific to USP14&UCHL5)- [137]Natural ProductCurcusone D-Low (Broad-spectrum) [138]Tanshinone I14.5 µMMedium (Specific to USP14&SARS-Cov PLpro) [139, 140]6-Gingerol-Undefined [50]EmergingARN1250218.4 µMPotential specificity [141]Note: The molecular structures of all compounds were obtained from the PubChem database (https://pubchem.ncbi.nlm.nih.gov/). Different kinds of USP14 inhibitor Note: The molecular structures of all compounds were obtained from the PubChem database (https://pubchem.ncbi.nlm.nih.gov/). Given the non-catalytic activities of USP14, technologies like PROTACs (Proteolysis Targeting Chimeras) that degrade the entire protein may hold drug development potential [116]. Considering the dual functionality of USP14, promoting the switch from classical ubiquitination to non-canonical proteasomal degradation or guiding it toward tumor-suppressive pathways are also potential directions [117, 118]. Given the powerful regulatory role of USP14 in tumors, targeting it holds significant clinical promise [119]. USP14 function is highly substrate-specific and context-dependent. Drawing from the classic roles of BAP1 and USP10 in maintaining genomic stability and the p53 axis [120–123], we speculate that the tumor-suppressive potential of USP14 may extend beyond negative regulation of the PI3K/AKT pathway. Future research should explore whether USP14 prevents driver mutations during tumor initiation by maintaining high-fidelity HR repair, or if it possesses CYLD-like activity to block inflammation-to-cancer signaling by removing non-degradative ubiquitin chains (e.g., K63 chains) [124]. Deeper investigation into these suppressive functions is crucial for defining clinical indications for USP14 inhibitors and preventing their misuse in subtypes where USP14 acts as a tumor suppressor. Beyond the established signaling axes discussed above, several emerging frontiers in cancer biology offer new opportunities and challenges for USP14 research. First, cuproptosis—a recently identified copper-dependent cell death pathway driven by aberrant aggregation of lipoylated mitochondrial proteins and loss of iron–sulfur cluster proteins—has attracted considerable attention as a potential therapeutic strategy [125, 126]. Given that USP14 governs proteasomal protein quality control, it is plausible that USP14 may influence the stability or turnover of cuproptosis-related proteins such as FDX1 or lipoylated components of the TCA cycle; however, this hypothesis remains to be tested experimentally. Second, PANoptosis, the coordinated activation of pyroptosis, apoptosis, and necroptosis, has emerged as a key mechanism linking innate immunity to tumor cell death [89]. USP14 has been shown to regulate both apoptotic signaling and the NF-κB pathway—two central nodes in PANoptotic execution—raising the possibility that USP14 may modulate the threshold or mode of PANoptotic cell death in specific tumor contexts. Third, as discussed in Section “Dynamic modeling and activity regulation of autoinhibitory and UBL domains”, lactylation of USP14 at Lys336 within the BL1 domain has been identified in hepatocellular carcinoma [14–17], suggesting a functional crosstalk between metabolic reprogramming and USP14 activity. Notably, lactate—the substrate for protein lactylation—is abundantly produced not only through the Warburg effect in tumor cells but also by tumor-associated microbiota [127]. The tumor microbiome has been increasingly recognized as a modulator of host immunity, drug metabolism, and treatment response [128]. Whether microbial metabolites within the tumor microenvironment can regulate USP14 activity through post-translational modifications such as lactylation, thereby influencing immune evasion or therapy resistance, represents an intriguing but unexplored direction. Collectively, these emerging areas highlight the need to position USP14 within the broader landscape of novel cell death modalities and host–microbiome interactions, which may ultimately reveal previously unrecognized therapeutic vulnerabilities. Conclusion As a critical USP family member, USP14 acts not only as an upstream factor directly regulating cancer proteins but also plays vital roles in shaping the tumor microenvironment and promoting therapy resistance. This article reviewed novel findings on USP14 from the past four to five years, including its new structural models and biological functions, and constructed a model of its role as a regulatory hub in cancer. Early research focused on its cell-autonomous oncogenic effects. However, recent advances have uncovered its tumor-suppressive roles, TME construction capabilities, contributions to therapy resistance, and non-canonical activities. These discoveries open new horizons for USP14-based cancer research. We believe that future therapies targeting USP14 phosphorylation and lactylation, novel inhibitors dynamically regulating conformation, and drugs targeting its non-canonical activities hold profound promise. Acknowledgements This work was supported by National Natural Science Foundation of China (No.81803895), Shandong Province Natural Science Foundation (ZR2021YQ57, ZR2024MH266). Author contributions Ruofeng Wang: Conceptualized and wrote the manuscript, prepared the figures and tables. Fang Yan: Clinical consultation, interpretation of clinical translational limitations, manuscript revision, and prepared a figure. Fengrui Duan: Clinical consultation, interpretation of therapeutic applicability and clinical limitations, manuscript revision, and prepared a table. Weikai Xia: Prepared the figures and tables. Lina Yang: Discussed the paper. Wenbo Wang: Discussed the paper. Zhenxiang Wang: Discussed the paper. Fulin Sun: Discussed the paper. Chunjuan Yu: Discussed the paper. Huhu Zhang: Discussed the paper. All authors approved the final manuscript. Data availability The datasets used and analyzed in this study are publicly available. TCGA data were obtained from The Cancer Genome Atlas database, and the processed expression and clinical data were downloaded from the UCSC Xena platform. No new datasets were generated in this study. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The datasets used and analyzed in this study are publicly available. TCGA data were obtained from The Cancer Genome Atlas database, and the processed expression and clinical data were downloaded from the UCSC Xena platform. No new datasets were generated in this study.